Clincosm LogoSign in Get a demo

Relationship Between Heart Failure With Preserved Ejection Fraction and Nonalcoholic Fatty Liver Disease.

Sponsor
Sohag University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05822622
Collaborator
(none)
100
Enrollment
2
Locations
4
Anticipated Duration (Months)
50
Patients Per Site
12.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The aim of our study to determine the demography, relation between patients with heart failure with preserved ejection fraction and those with nonalcoholic fatty liver disease in Sohag university hospital.

Condition or Disease Intervention/Treatment Phase
  • Other: echocardiography

Detailed Description

type of the study cross sectional study to study the relationship between heart failure with preserved ejection fraction and nonalcoholic fatty liver disease.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
100 participants
Observational Model:
Other
Time Perspective:
Cross-Sectional
Official Title:
Relationship Between Heart Failure With Preserved Ejection Fraction and Nonalcoholic Fatty Liver Disease.
Anticipated Study Start Date :
Apr 29, 2023
Anticipated Primary Completion Date :
Jul 1, 2023
Anticipated Study Completion Date :
Aug 30, 2023

Arms and Interventions

Arm Intervention/Treatment
HFpEF(heart failure with preserved ejection fraction)

chronic heart failure with echocardiographic finding of LVEF (left ventricular ejection fraction) equal or more than 50% , diagnostic test :Abdominal ultrasound and transient elastography for detecting non alcoholic fatty liver disease .

Other: echocardiography
to determine finding of heart failure with preserved ejection fraction and non alcoholic fatty liver disease
Other Names:
  • abdominal ultrasound and transient elastography

    		•
    NAFLD(non alcoholic fatty liver disease)

    ultrasound and transient elastographic finding of fatty liver disease, diagnostic test :echocardiography to determine heart failure with preserved ejection fraction .

    Other: echocardiography
    to determine finding of heart failure with preserved ejection fraction and non alcoholic fatty liver disease
    Other Names:
  • abdominal ultrasound and transient elastography

    		•

    Outcome Measures

    Primary Outcome Measures

    1. collection of results of echocardiography (those detect HFpEF) with abdominal ultrasound and transient elastography results (those detect NAFLD) and find relationship between the results. [up to 28 weeks.]

      looking for relationship between echocardiographic findings (that detect heart failure with preserved ejection fraction) and finding in abdominal ultrasound and transient elastography (detection of nonalcoholic fatty liver disease) to detect the relationship between those two diseases.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 90 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes

    Inclusion Criteria: clinical diagnosis of heart failure with preserved ejection fraction.

    clinical diagnosis of nonalcoholic fatty liver disease. -

    Exclusion Criteria: rheumatic heart disease ,congenital heart disease , ischemic heart disease ,heart failure with reduced ejection fraction , hepatitis B virus , hepatitis C virus .

    -

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Asmaa elsayed khalifa Sohag El Monshah Egypt 82515
    2 Asmaa E khalifa Sohag Egypt 82515

    Sponsors and Collaborators

    • Sohag University

    Investigators

    • Study Chair: Aml K Ahmed, A professor, Sohag university hospital
    • Study Chair: Alshimaa L Hamed, lecturer, Sohag university hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Asmaa Elsayed Khalifa, resident of internal medicine, Sohag University
    ClinicalTrials.gov Identifier:
    NCT05822622
    Other Study ID Numbers:
    • Soh-Med-23-02-03
    First Posted:
    Apr 21, 2023
    Last Update Posted:
    Apr 21, 2023
    Last Verified:
    Apr 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Liver Diseases
    Fatty Liver
    Non-alcoholic Fatty Liver Disease
    Heart Failure

    Study Results

    No Results Posted as of Apr 21, 2023